Satsuma Pharmaceuticals Inc. [NASDAQ: STSA] loss 0.00% on the last trading session, reaching $4.33 price per share at the time.
Satsuma Pharmaceuticals Inc. represents 17.40 million in outstanding shares, while the company has a total market value of $77.81 million with the latest information. STSA stock price has been found in the range of $4.28 to $4.55.
If compared to the average trading volume of 2.22M shares, STSA reached a trading volume of 1157534 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Satsuma Pharmaceuticals Inc. [STSA]:
SVB Leerink have made an estimate for Satsuma Pharmaceuticals Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on September 11, 2020. While these analysts kept the previous recommendation, Mizuho raised their target price from $32 to $4. The new note on the price target was released on September 11, 2020, representing the official price target for Satsuma Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $33 to $4, while Credit Suisse kept a Neutral rating on STSA stock.
The Average True Range (ATR) for Satsuma Pharmaceuticals Inc. is set at 1.52 The Price to Book ratio for the last quarter was 0.80, with the Price to Cash per share for the same quarter was set at 5.21.
Trading performance analysis for STSA stock
Satsuma Pharmaceuticals Inc. [STSA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.65. With this latest performance, STSA shares dropped by -81.91% in over the last four-week period, additionally sinking by -73.73% over the last 6 months – not to mention a drop of -71.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for STSA stock in for the last two-week period is set at 14.01, with the RSI for the last a single of trading hit 10.54, and the three-weeks RSI is set at 18.98 for Satsuma Pharmaceuticals Inc. [STSA]. The present Moving Average for the last 50 days of trading for this stock 20.56, while it was recorded at 4.49 for the last single week of trading, and 21.97 for the last 200 days.
Satsuma Pharmaceuticals Inc. [STSA]: A deeper dive into fundamental analysis
Return on Total Capital for STSA is now -46.30, given the latest momentum, and Return on Invested Capital for the company is -45.95. Return on Equity for this stock declined to -54.60, with Return on Assets sitting at -42.48. When it comes to the capital structure of this company, Satsuma Pharmaceuticals Inc. [STSA] has a Total Debt to Total Equity ratio set at 4.27. Additionally, STSA Total Debt to Total Capital is recorded at 4.10, with Total Debt to Total Assets ending up at 3.90. Long-Term Debt to Equity for the company is recorded at 2.56, with the Long-Term Debt to Total Capital now at 2.45.
Reflecting on the efficiency of the workforce at the company, Satsuma Pharmaceuticals Inc. [STSA] managed to generate an average of -$1,657,353 per employee.Satsuma Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.10 and a Current Ratio set at 15.10.
Satsuma Pharmaceuticals Inc. [STSA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Satsuma Pharmaceuticals Inc. posted -2.26/share EPS, while the average EPS was predicted by analysts to be reported at -1.01/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -123.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for STSA.
An analysis of insider ownership at Satsuma Pharmaceuticals Inc. [STSA]
There are presently around $60 million, or 79.90% of STSA stock, in the hands of institutional investors. The top three institutional holders of STSA stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 4,681,858, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; TPG GROUP HOLDINGS (SBS) ADVISORS, INC., holding 1,885,939 shares of the stock with an approximate value of $8.17 million in STSA stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $6.97 million in STSA stock with ownership of nearly -22.616% of the company’s market capitalization.
44 institutional holders increased their position in Satsuma Pharmaceuticals Inc. [NASDAQ:STSA] by around 1,572,884 shares. Additionally, 10 investors decreased positions by around 1,582,917 shares, while 5 investors held positions by with 10,634,307 shares. The mentioned changes placed institutional holdings at 13,790,108 shares, according to the latest SEC report filing. STSA stock had 23 new institutional investments in for a total of 631,313 shares, while 3 institutional investors sold positions of 61,302 shares during the same period.